Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 18/20 | 0.82 |
| ▸ | MMP1 | P03956 | 15/20 | 0.82 |
| ▸ | MMP2 | P08253 | 14/20 | 0.82 |
| ▸ | MMP7 | P09237 | 5/20 | 0.82 |
| ▸ | MMP9 | P14780 | 4/20 | 0.82 |
| ▸ | MMP14 | P50281 | 2/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
| ▸ | MMP13 | P45452 | 1/20 | 0.71 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.71 |
| ▸ | Q9HBH1 | 1/20 | 0.62 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398532 | 0.91 | MMP3 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| SCHEMBL14545737 | 0.91 | MMP3 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL31060724 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL5491595 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL4634066 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL8188276 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL4633699 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL8189171 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| Ro-319790 SCHEMBL5494052 | 0.83 | MMP1 (1.00) | MMP3MMP1MMP2MMP7MMP9 | |
| SCHEMBL4816160 | 0.81 | MMP2 (0.70) | MMP3MMP1MMP2MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323563-B2 | Hydroxamic acid derivatives as antibacterials | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323563-B2 | Hydroxamic acid derivatives as antibacterials | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323563-B2 | Hydroxamic acid derivatives as antibacterials | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| EP-1754477-A2 | Hydroxamic acid derivatives as antibacterials | Vernalis (Oxford) Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060211732-A1 | Hydroxamic acid derivatives as antibacterials | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2006-09-21 | — | — | US | disclosed |
| US-6441042-B1 | HYDROXYAMIDES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211732-A1 | Hydroxamic acid derivatives as antibacterials | SLC7A1, EGLN2, PIGS | MMP3 53/4885MMP1 19/4885MMP2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.